Analyst Consensus ?
ConsensusBuy33 ratings
Bullish2678.8%
Neutral721.2%
Bearish00.0%
MetLife, Inc. · MET · FY2025 Q4 · Calendar Q1 2026
MetLife pairs record retirement volumes with maintained 2026 targets
The supplied analysis supports a constructive but qualified view of MetLife’s operating trajectory: retirement volumes, international growth, asset-management scale, and efficiency initiatives support continued earnings growth, while underwriting, macro, integration, and workforce risks temper the outlook.
Reported After market closeNYSEFinancial Services
$61.26B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$2.58
Consensus $2.34
EPS surprise
+10.3%
Reported versus consensus
Reported revenue
$23.81B
Consensus $27.22B
Revenue surprise
-12.5%
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
-3.4%
Event window
SPY move
-1.2%
Same window
Abnormal move
-2.2%
Stock minus SPY
Volume
2.4×
Versus trailing sessions
Subsequent drift
-4.6%
Up to 20 sessions
METSPY benchmark
Ask FN2 about MET FY2025 Q4
Transcript, numbers and history already loaded
Why did MET fall 3.4% after beating EPS estimates in FY2025 Q4?What changed in MET's guidance and outlook in FY2025 Q4?Give me the bull and bear case for MET after FY2025 Q4 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior-quarter analysis, MetLife has closed the PineBridge acquisition and established MetLife Investment Management as a standalone segment. The current analysis also emphasizes record annual pension risk transfer origination, international sales growth, and maintained 2026 targets, while adding integration and disability-severity considerations.
Guidance delta
Management maintained its outlook, including double-digit adjusted EPS growth and 15–17% ROE in 2026, with a 12.1% direct expense-ratio target for 2026.
Key takeaways
- The current analysis describes adjusted EPS growth and 2025 ROE as meeting five-year targets.
- International sales growth, especially in Asia and Latin America, remained a central driver.
- PineBridge is now integrated into a standalone MetLife Investment Management segment, adding scale while creating integration considerations.
Management priorities
- Sustain double-digit adjusted EPS growth and 15–17% ROE in 2026.
- Expand pension risk transfer, retirement, and annuity reinsurance flows.
- Scale MetLife Investment Management and digital platforms while improving efficiency.
Follow MET with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$95.2Current
$68Low
$94Average
$145High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Sep 30, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Piper Sandler | Overweight | Neutral | Upgrade | Sep 22, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Aug 24, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Aug 19, 2026 |
| Keefe, Bruyette & Woods | Outperform | Outperform | Maintain | Aug 11, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Aug 11, 2026 |
| Barclays | Overweight | Overweight | Maintain | Aug 6, 2026 |
| TD Cowen | Buy | Buy | Maintain | Jul 22, 2026 |
| Evercore ISI Group | In Line | In Line | Maintain | Jul 13, 2026 |
| Jefferies | Buy | Buy | Maintain | Jul 10, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Jul 9, 2026 |
| UBS | Buy | Buy | Maintain | Jul 8, 2026 |
| B of A Securities | Buy | Buy | Maintain | Apr 14, 2026 |
| Citigroup | Buy | Buy | Maintain | Jul 23, 2024 |
| Argus Research | Buy | Buy | Maintain | May 22, 2024 |
| Goldman Sachs | Buy | Buy | Maintain | Jan 9, 2024 |
| RBC Capital | Outperform | Outperform | Maintain | Aug 4, 2023 |
| Raymond James | Perform | Market Perform | Maintain | Sep 22, 2022 |
| Credit Suisse | Outperform | Outperform | Maintain | Aug 22, 2022 |
| Wolfe Research | Outperform | Peer Perform | Upgrade | Aug 19, 2022 |
| Deutsche Bank | Hold | Hold | Maintain | Apr 12, 2019 |
| Sandler O'Neill | Hold | Buy | Downgrade | Mar 19, 2019 |
| Bank of America | Buy | Neutral | Upgrade | Jan 16, 2019 |
| B. Riley Securities | Neutral | Neutral | Maintain | Jul 16, 2018 |
| B. Riley FBR | Neutral | Neutral | Maintain | Jul 16, 2018 |
| Atlantic Equities | Overweight | Neutral | Upgrade | Mar 26, 2018 |
| Argus | Buy | Buy | Maintain | Nov 6, 2017 |
| FBR Capital | Neutral | Buy | Downgrade | Oct 10, 2017 |
| Macquarie | Outperform | Outperform | Maintain | Feb 4, 2016 |
| Keefe Bruyette & Woods | Outperform | Outperform | Maintain | Oct 12, 2015 |
| Sterne Agee | Buy | Buy | Maintain | Oct 13, 2014 |
| Drexel Hamilton | Buy | Buy | Maintain | Jul 7, 2014 |
| Janney Montgomery Scott | Buy | Neutral | Upgrade | Jan 3, 2014 |
| Janney Capital | Buy | Neutral | Upgrade | Jan 3, 2014 |
Named analyst price targets
Upside is calculated against the persisted current price $95.2. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Piper Sandler | Paul Newsome | $110 | $96.64 | +15.5% | Sep 22, 2026 |
| Morgan Stanley | Bob Huang | $111 | $95.75 | +16.6% | Aug 24, 2026 |
| Wells Fargo | Analyst unavailable | $109 | $96.73 | +14.5% | Aug 19, 2026 |
| Barclays | Analyst unavailable | $97 | $96.26 | +1.9% | Aug 6, 2026 |
| Atlantic Equities | Analyst unavailable | $103 | $92.44 | +8.2% | Jul 15, 2026 |
| Jefferies | Suneet Kamath | $103 | $91.15 | +8.2% | Jul 10, 2026 |
| UBS | Michael Ward | $105 | $90.27 | +10.3% | Jul 8, 2026 |
| Barclays | Alex Scott | $94 | $90.46 | -1.3% | Jul 7, 2026 |
| Morgan Stanley | Analyst unavailable | $103 | $90.93 | +8.2% | Jul 6, 2026 |
| Piper Sandler | Analyst unavailable | $90 | $88.03 | -5.5% | Jun 24, 2026 |
| Piper Sandler | Analyst unavailable | $86 | $84.06 | -9.7% | May 26, 2026 |
| Morgan Stanley | Bob Huang | $93 | $83.5 | -2.3% | May 21, 2026 |
| Wells Fargo | Analyst unavailable | $95 | $77.98 | -0.2% | May 12, 2026 |
| Mizuho Securities | Yaron Kinar | $95 | $78.82 | -0.2% | May 8, 2026 |
| Barclays | Alex Scott | $93 | $80.16 | -2.3% | May 7, 2026 |
| Mizuho Securities | Yaron Kinar | $93 | $74.63 | -2.3% | Apr 13, 2026 |
| Evercore ISI | Analyst unavailable | $96 | $74.65 | +0.8% | Apr 9, 2026 |
| UBS | Analyst unavailable | $102 | $74.65 | +7.1% | Apr 9, 2026 |
| Mizuho Securities | Analyst unavailable | $100 | $78.89 | +5.0% | Feb 12, 2026 |
| Evercore ISI | Thomas Gallagher | $95 | $77.92 | -0.2% | Feb 10, 2026 |
| UBS | Analyst unavailable | $98 | $78.01 | +2.9% | Feb 5, 2026 |
| Mizuho Securities | Analyst unavailable | $102 | $77.08 | +7.1% | Jan 14, 2026 |
| Wells Fargo | Elyse Greenspan | $97 | $78.32 | +1.9% | Jan 13, 2026 |
| UBS | Analyst unavailable | $94 | $79.79 | -1.3% | Jan 8, 2026 |
| Barclays | Analyst unavailable | $90 | $79.47 | -5.5% | Jan 8, 2026 |
| Evercore ISI | Analyst unavailable | $97 | $81.77 | +1.9% | Jan 6, 2026 |
| Mizuho Securities | Analyst unavailable | $101 | $82.62 | +6.1% | Dec 15, 2025 |
| Morgan Stanley | Analyst unavailable | $101 | $83.22 | +6.1% | Dec 15, 2025 |
| Barclays | Analyst unavailable | $98 | $82.75 | +2.9% | Oct 8, 2025 |
| Morgan Stanley | Bob Huang | $97 | $82.7 | +1.9% | Oct 7, 2025 |
| Piper Sandler | John Barnidge | $84 | $79.07 | -11.8% | Sep 19, 2025 |
| Wolfe Research | Tracy Benguigui | $95 | $80.46 | -0.2% | Sep 15, 2025 |
| Morgan Stanley | Bob Huang | $98 | $77.74 | +2.9% | Jul 14, 2025 |
| Piper Sandler | John Barnidge | $94 | $82.49 | -1.3% | Apr 2, 2025 |
| Morgan Stanley | Analyst unavailable | $109 | $86.18 | +14.5% | Feb 28, 2025 |
| Piper Sandler | John Barnidge | $92 | $81.78 | -3.4% | Oct 2, 2024 |
| Barclays | Alex Scott | $91 | $77.52 | -4.4% | Sep 4, 2024 |
| Bank of America Securities | Joshua Shanker | $96 | $76.85 | +0.8% | Aug 1, 2024 |
| Morgan Stanley | Bob Huang | $83 | $69.92 | -12.8% | Jul 10, 2024 |
| Argus Research | Kevin Heal | $80 | $73.15 | -16.0% | May 22, 2024 |
| Piper Sandler | John Barnidge | $82 | $70.94 | -13.9% | May 6, 2024 |
| CFRA | Catherine Seifert | $77 | $72.67 | -19.1% | Mar 13, 2024 |
| Goldman Sachs | Alex Scott | $80 | $68.92 | -16.0% | Jan 8, 2024 |
| Mizuho Securities | Brett Linzey | $145 | $63.79 | +52.3% | Sep 14, 2023 |
| Morgan Stanley | Analyst unavailable | $90 | $72.68 | -5.5% | Feb 2, 2023 |
| Morgan Stanley | Analyst unavailable | $88 | $71.35 | -7.6% | Jan 10, 2023 |
| Goldman Sachs | Analyst unavailable | $78 | $73.58 | -18.1% | Jan 9, 2023 |
| J.P. Morgan | Analyst unavailable | $80 | $73.58 | -16.0% | Jan 6, 2023 |
| Jefferies | Analyst unavailable | $82 | $73.61 | -13.9% | Dec 9, 2022 |
| Morgan Stanley | Analyst unavailable | $87 | $74.01 | -8.6% | Nov 17, 2022 |
| Credit Suisse | Analyst unavailable | $77 | $67.39 | -19.1% | Aug 22, 2022 |
| Morgan Stanley | Analyst unavailable | $83 | $67.25 | -12.8% | Aug 17, 2022 |
| Morgan Stanley | Analyst unavailable | $79 | $64.14 | -17.0% | Aug 4, 2022 |
| Barclays | Analyst unavailable | $75 | $57.79 | -21.2% | Jul 14, 2022 |
| Evercore ISI | Analyst unavailable | $80 | $61.4 | -16.0% | Jul 6, 2022 |
| Morgan Stanley | Analyst unavailable | $78 | $61.58 | -18.1% | Jul 6, 2022 |
| Wolfe Research | Charles Lederer | $74 | $61.75 | -22.3% | Jun 22, 2022 |
| Morgan Stanley | Analyst unavailable | $80 | $67.23 | -16.0% | May 5, 2022 |
| Evercore ISI | Thomas Gallagher | $75 | $64.18 | -21.2% | Jan 5, 2022 |
| Goldman Sachs | Alex Scott | $77 | $58.92 | -19.1% | Dec 2, 2021 |
| Credit Suisse | Andrew Kligerman | $68 | $63.12 | -28.6% | May 13, 2021 |
| Argus Research | Kevin Heal | $72 | $65.2 | -24.4% | May 7, 2021 |
Track every rating change on MET the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationMetLife, Inc. operates as a leading global financial services entity, delivering an extensive array of services encompassing insurance, annuities, employee benefits, and asset management. The company manages its operations through five primary divisions: the U.S., Asia, Latin America, Europe, the Middle East and Africa (EMEA), and MetLife Holdings. Its broad insurance offerings include life, dental, group short-term and long-term disability, individual disability, pet, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans. MetLife also supports employers with administrative services-only (ASO) arrangements. Furthermore, it provides sophisticated financial instruments such as general and separate account contracts, synthetic guaranteed interest contracts, and private floating rate funding agreements.…
Historical context
All MET earningsFinancial Services peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| PUK Prudential plc | FY2026 Q2 · Calendar Q3 2026 | -40.9% | -0.5% | Prudential sustains growth and capital returns focus in H1 2026 |
| CM Canadian Imperial Bank of Commerce | FY2026 Q3 · Calendar Q3 2026 | +8.9% | -2.8% | CIBC Q3: Broad growth, resilient credit and expanded AI rollout |
| TD The Toronto-Dominion Bank | FY2026 Q3 · Calendar Q3 2026 | +13.8% | +1.4% | TD emphasizes growth investments alongside disciplined capital management |
| RY Royal Bank of Canada | FY2026 Q3 · Calendar Q3 2026 | +6.2% | -1.3% | RBC reports record Q3 earnings while investing for growth |
| AFRM Affirm Holdings, Inc. | FY2026 Q4 · Calendar Q3 2026 | +1230.3% | +0.3% | Affirm's most profitable quarter shifts focus to product execution |
Latest beats and misses
Who reports nextBeat on EPS
- COSTFY2026 Q4 · September 24, 2026+3.2% EPS+2.9% move
- SNXFY2026 Q3 · September 24, 2026+20.9% EPS-9.9% move
- DRIFY2027 Q1 · September 24, 20260.0% EPS-3.0% move
- CTASFY2027 Q1 · September 23, 2026+3.0% EPS-3.4% move
- PAYXFY2027 Q1 · September 23, 2026+1.5% EPS-8.8% move
- GISFY2027 Q1 · September 23, 2026+4.6% EPS+1.0% move
Get the MET recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:36:15.940040+00:00
- Polygon adjusted daily market bars · 2026-09-30T04:46:07.235017+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-09-30T04:46:07.231734+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-09-30. For educational purposes only; not investment advice.